Join
Live feed
·
PRReleasevia Quantisnow
Zura Bio Limited logo

Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program

ByQuantisnow·Wall Street's wire, on your screen.
ZURA· Zura Bio Limited
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ZURA (Zura Bio Limited) and more on Quantisnow.